1. Home
  2. RIGL vs EFR Comparison

RIGL vs EFR Comparison

Compare RIGL & EFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • EFR
  • Stock Information
  • Founded
  • RIGL 1996
  • EFR 2003
  • Country
  • RIGL United States
  • EFR United States
  • Employees
  • RIGL N/A
  • EFR N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • EFR Trusts Except Educational Religious and Charitable
  • Sector
  • RIGL Health Care
  • EFR Finance
  • Exchange
  • RIGL Nasdaq
  • EFR Nasdaq
  • Market Cap
  • RIGL 335.5M
  • EFR 344.0M
  • IPO Year
  • RIGL 2000
  • EFR N/A
  • Fundamental
  • Price
  • RIGL $38.85
  • EFR $11.71
  • Analyst Decision
  • RIGL Buy
  • EFR
  • Analyst Count
  • RIGL 5
  • EFR 0
  • Target Price
  • RIGL $38.20
  • EFR N/A
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • EFR 88.6K
  • Earning Date
  • RIGL 08-05-2025
  • EFR 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • EFR 9.43%
  • EPS Growth
  • RIGL N/A
  • EFR N/A
  • EPS
  • RIGL 5.43
  • EFR 1.69
  • Revenue
  • RIGL $267,921,000.00
  • EFR N/A
  • Revenue This Year
  • RIGL $59.93
  • EFR N/A
  • Revenue Next Year
  • RIGL N/A
  • EFR N/A
  • P/E Ratio
  • RIGL $7.14
  • EFR $7.74
  • Revenue Growth
  • RIGL 105.62
  • EFR N/A
  • 52 Week Low
  • RIGL $12.66
  • EFR $10.95
  • 52 Week High
  • RIGL $43.72
  • EFR $13.29
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • EFR 43.60
  • Support Level
  • RIGL $39.00
  • EFR $11.64
  • Resistance Level
  • RIGL $42.08
  • EFR $11.79
  • Average True Range (ATR)
  • RIGL 2.32
  • EFR 0.09
  • MACD
  • RIGL -0.37
  • EFR 0.01
  • Stochastic Oscillator
  • RIGL 53.26
  • EFR 60.00

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest

Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.

Share on Social Networks: